Kurve Technology, Inc., a leading developer of nasal drug delivery devices, and Schering-Plough Corporation, a global science-based health care company, announced a new agreement that expands Schering-Plough's evaluation of, and option for exclusivity rights to, Kurve Technology's Controlled Particle Dispersion platform from a single field to multiple fields of use.

"We are extremely pleased with Schering-Plough's continued and expanded interest in our nasal delivery technology platforms," said Marc Giroux, chairman and chief executive officer of Kurve Technology, Inc. "This agreement is another significant step in our efforts of working with pharmaceutical companies to develop the most innovative intranasal drug/device combinations in the industry."

Kurve Technology's Controlled Particle Dispersion (CPD) contains six critical-to function design parameters that enable modification of deposition and droplet characteristics. The result is a flexible intranasal technology platform that can deliver virtually any liquid drug -solution or suspension - regardless of formulation characteristics including viscocity, surface tension or molecule size. CPD enables pharmaceutical companies to deliver topical, systemic, nose-to-brain drugs and vaccines with minimal peripheral deposition to the lungs and stomach.

CPD powers Kurve Technology's ViaNase electronic atomizer line.

Kurve Technology, Inc. offers pharmaceutical companies innovative nasal delivery technologies for topical, systemic, nose-to-brain medical and vaccine therapies. Kurve's Controlled Particle Dispersion (CPD) technology intranasally delivers formulations with far greater efficacy and efficiency than traditional methods.